A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
150estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-22 | actual | When the study began enrolling |
| Primary completion | 2024-07-26 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
Intervention
- Drug: Mavacamten
Primary outcomes
what the primary-completion date above is the date OFNew York Heart Association (NYHA) functional class
measured Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, and in increments of 12 weeks thereafter from index
Left ventricular outflow tract (LVOT) gradient and associated parameters
measured Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, and in increments of 12 weeks thereafter from index
Left ventricular ejection fraction (LVEF) and associated parameters
measured Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, and in increments of 12 weeks thereafter from index
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed